To support this growth, TileDB opened a new office in New York City, in addition to the company’s current headquarters in Cambridge ... Prior to joining Alexion in 2015, George was employed by Merck & ...

To support this growth, TileDB opened a new office in New York City, in addition to the company's current headquarters in Cambridge ... Prior to joining Alexion in 2015, George was employed by Merck & ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

German companies including Merck and ZEISS expressed strong confidence and high hopes for the Chinese market at the China ...

Vietnam Expands for 2025 with Addition of New Hall - The largest edition yet, nearly double the size of the 2023 edition. - ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

PhotonPay announced that it has become a Mastercard issuer in Hong Kong. The two parties will integrate their respective professional capabilities and resource advantages and work together to provide ...

"Many multinationals with headquarters in Pudong have also played a significant ... to seek synergies in various fields," she added. Marc Horn, president of Merck China, also spoke highly of China's ...

Islatravir is Merck's investigational nucleoside reverse transcriptase ... Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif. For more than 35 years, Gilead ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...